Healthy volunteers needed to test aramchol absorption
NCT ID NCT07251712
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing how the body absorbs a single dose of aramchol, a drug being studied for liver disease. Researchers will give 32 healthy volunteers two different single doses of aramchol meglumine tablets and measure drug levels in their blood. The goal is to understand how much drug gets into the bloodstream and how long it stays there.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aramchol (aramchol meglumine tablet)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hammersmith Medicines Research (HMR)
RECRUITINGLondon, NW10 7EW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test